Evidence map›Paper›PMID 36317930›Full record

ArticleAntimicrobial agents and chemotherapy2022

Apparent Absence of Selective Pressure on Pneumocystis jirovecii Organisms in Patients with Prior Methotrexate Exposure.

Pierre L Bonnet, Solène Le Gal, Chloé Gautier, Claire V Hoffmann, Nathan Le Nan, André Happe, Rozenn Le Berre, Alain Saraux, Gilles Nevez

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Pierre L BonnetLaboratory of Parasitology and Mycology, Brest University Hospital, Brest, France.ORCID 0000-0002-2965-648X
Solène Le GalLaboratory of Parasitology and Mycology, Brest University Hospital, Brest, France.
Chloé GautierFungal Respiratory Infections (FRI) Research Unit, University of Angers, University of Western Brittany, Brest, France.
Claire V HoffmannLaboratory of Parasitology and Mycology, Brest University Hospital, Brest, France.
Nathan Le NanLaboratory of Parasitology and Mycology, Brest University Hospital, Brest, France.
André HappeClinical Data Center, Brest University Hospital, Brest, France.
Rozenn Le BerreDepartment of Internal and Respiratory Medicine, Brest University Hospital, Brest, France.
Alain SarauxDepartment of Rheumatology, Brest University Hospital, Brest, France.
Gilles NevezLaboratory of Parasitology and Mycology, Brest University Hospital, Brest, France.ORCID 0000-0001-5888-6017
Université de Bretagne Occidentale · FRInserm · FRCentre Hospitalier Régional Universitaire de Brest · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pneumocystis jirovecii infections occur in patients treated with methotrexate (MTX) because of immunosuppressive effects of this highly potent dihydrofolate reductase (DHFR) inhibitor. Conversely, MTX may act as an anti

Indexed as

Folic Acid AntagonistsPneumocystis cariniiPneumocystis InfectionsHumansMethotrexatePolymorphism, Single NucleotideTetrahydrofolate DehydrogenaseFolic Acid AntagonistsMethotrexateTetrahydrofolate Dehydrogenasedhfrdihydrofolate reductasegenetic diversitymethotrexatePneumocystis jirovecii

Identifiers

PMID36317930
PMCPMC9765006
OpenAlexW4307845768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.